nimotuzumab
biocon,daiichi sankyo,oncoscience
['nimotuzumab']
nimotuzumab +ct+ rt versus ct+rt. nimo has an os benefit. #asco2022. but no lrfs benefit
Professor, Head and Neck-Medical Oncologist, Neuro-Medical Oncologist, Thoracic-Medical Oncologist,Researcher,Immunotherapy, Statistics and Phase 1/2/3 studies